Literature DB >> 19530914

Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.

Kimberly A Kraynyak1, Michele A Kutzler, Neil J Cisper, Dominick J Laddy, Matthew P Morrow, Thomas A Waldmann, David B Weiner.   

Abstract

Plasmid-encoded DNA vaccines appear to be a safe and effective method for delivering antigen; however, the immunogenicity of such vaccines is often suboptimal. Cytokine adjuvants including interleukin (IL)-12, RANTES, granulocyte-macrophage colony-stimulating factor, IL-15, and others have been used to augment the immune response against DNA vaccines. In particular, IL-15 binds to a unique high-affinity receptor, IL-15R alpha; is trans-presented to CD8(+) T cells expressing the common betagamma chain; and has been shown to play a role in the generation, maintenance, and proliferation of antigen-specific CD8(+) T cells. In this study, we took the unique approach of using both a cytokine and its receptor as an adjuvant in an HIV-1 vaccine strategy. To study IL-15R alpha expression, a unique monoclonal antibody (KK1.23) was generated to confirm receptor expression in vitro. Coimmunization of IL-15 and IL-15R alpha plasmids with HIV-1 antigenic plasmids in mice enhanced the antigen-specific immune response 2-fold over IL-15 immunoadjuvant alone. Furthermore, plasmid-encoded IL-15R alpha augments immune responses in the absence of IL-15, suggesting its role as a novel adjuvant. Moreover, pIL-15R alpha enhanced the cellular, but not the humoral, immune response as measured by antigen-specific IgG antibody. This is the first report describing that IL-15R alpha itself can act as an adjuvant by enhancing an antigen-specific T cell response. Uniquely, pIL-15 and pIL-15R alpha adjuvants combined, but not the receptor alpha chain alone, may be useful as a strategy for generating and maintaining memory CD8(+) T cells in a DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19530914      PMCID: PMC2829284          DOI: 10.1089/hum.2009.025

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  63 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

3.  Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure.

Authors:  Toshiki Yajima; Hitoshi Nishimura; Ryotaro Ishimitsu; Taketo Watase; Dirk H Busch; Eric G Pamer; Hiroyuki Kuwano; Yasunobu Yoshikai
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.

Authors:  Zheng Wu; Hai-Hui Xue; Jérôme Bernard; Rong Zeng; Dmitry Issakov; Julie Bollenbacher-Reilley; Igor M Belyakov; Sangkon Oh; Jay A Berzofsky; Warren J Leonard
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

5.  The IL-15R alpha chain signals through association with Syk in human B cells.

Authors:  E Bulanova; V Budagian; T Pohl; H Krause; H Dürkop; R Paus; S Bulfone-Paus
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

6.  Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.

Authors:  Anne C Moore; Wing-pui Kong; Bimal K Chakrabarti; Gary J Nabel
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Authors:  M K Kennedy; M Glaccum; S N Brown; E A Butz; J L Viney; M Embers; N Matsuki; K Charrier; L Sedger; C R Willis; K Brasel; P J Morrissey; K Stocking; J C Schuh; S Joyce; J J Peschon
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

9.  Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells.

Authors:  Todd C Becker; E John Wherry; David Boone; Kaja Murali-Krishna; Rustom Antia; Averil Ma; Rafi Ahmed
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  T cell-independent interleukin 15Ralpha signals are required for bystander proliferation.

Authors:  J P Lodolce; P R Burkett; D L Boone; M Chien; A Ma
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  12 in total

1.  Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques.

Authors:  Matthew P Morrow; Jian Yan; Panyupa Pankhong; Bernadette Ferraro; Mark G Lewis; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Clin Vaccine Immunol       Date:  2010-08-04

2.  Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.

Authors:  Tommaso Lorenzi; Rebecca H Chisholm; Matteo Melensi; Alexander Lorz; Marcello Delitala
Journal:  Immunology       Date:  2015-08-02       Impact factor: 7.397

3.  Expression of interleukin-15 and interleukin-15Rα in monocytes of HIV type 1-infected patients with different courses of disease progression.

Authors:  Maciej Tarkowski; Laurenzia Ferraris; Sara Martone; Francesco Strambio de Castillia; Donatella Misciagna; Renata I Mazzucchelli; Emanuela Lattuada; Giuseppe Paraninfo; Massimo Galli; Agostino Riva
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

4.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

Review 5.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

6.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Authors:  Spyros A Kalams; Scott D Parker; Marnie Elizaga; Barbara Metch; Srilatha Edupuganti; John Hural; Stephen De Rosa; Donald K Carter; Kyle Rybczyk; Ian Frank; Jonathan Fuchs; Beryl Koblin; Denny H Kim; Patrice Joseph; Michael C Keefer; Lindsey R Baden; John Eldridge; Jean Boyer; Adam Sherwat; Massimo Cardinali; Mary Allen; Michael Pensiero; Chris Butler; Amir S Khan; Jian Yan; Niranjan Y Sardesai; James G Kublin; David B Weiner
Journal:  J Infect Dis       Date:  2013-07-08       Impact factor: 5.226

7.  Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Authors:  Spyros A Kalams; Scott Parker; Xia Jin; Marnie Elizaga; Barbara Metch; Maggie Wang; John Hural; Michael Lubeck; John Eldridge; Massimo Cardinali; William A Blattner; Magda Sobieszczyk; Vinai Suriyanon; Artur Kalichman; David B Weiner; Lindsey R Baden
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

Review 8.  Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Authors:  Charles B Chesson; Andrew Zloza
Journal:  Nanomedicine (Lond)       Date:  2017-11-03       Impact factor: 5.307

9.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.

Authors:  J C Morris; C A Ramlogan-Steel; P Yu; B A Black; P Mannan; J P Allison; T A Waldmann; J C Steel
Journal:  Gene Ther       Date:  2014-02-27       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.